Trial · NCT06516887
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
NCT06516887, Phase 1, Phase 2, Terminated, The University of Texas Health Science Center at San Antonio
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma. Trials, record NCT06516887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06516887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
- NCT number
- NCT06516887
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Conditions
- Advanced Lung Adenocarcinoma
- Interventions
- bemcentinib, pacritinib
- First posted
- 2024-07-24
- Last updated
- 2026-05-26
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Up to 48 months | PFS will be defined as the time from the date of randomization to the date of disease progression or death (any cause), whichever occurs first. Subjects completing study follow-up or initiating a new anticancer therapy prior to documented PD will be censored in the PFS analysis at the last known date the subject was documented progression free prior to completing follow-up or initiating the new therapy. |
| Primary | Overall Response Rate | Up to 48 months | Overall response rate is defined as the proportion of patients who have a partial or complete response to therapy. |
| Secondary | Overall Survival (OS) | Up to 48 months | The time from randomization to death from any cause |
| Secondary | Clinical Benefit Rate | Up to 48 months | The percentage of patients with metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA269766 | Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments | TAVERNA, JOSEPHINE A | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER | NATIONAL CANCER INSTITUTE | 2023 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06516887
GET https://conductscience.org/api/trials/v1/NCT06516887/registered